• Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington’s disease (HD) and chorea through Teva’s Honestly HD program
• HD is a rare, progressive genetic disorder often described as a combination of ALS, Parkinson’s and Alzheimer’s, which manifests in motor, cognitive, and emotional symptoms1
• Teva’s Honestly HD program provides educational information about HD chorea, a symptom occurring in up to 90% of people with HD,2 to help those living with the condition and their care partners better navigate its challenges

PARSIPPANY, N.J., and TEL AVIV, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a partnership with actor, comedian and advocate, Will Forte, to increase awareness of Huntington’s disease (HD). HD, a rare, progressive neurological disorder, affects more than 41,000 people in the U.S. and causes cognitive, behavioral and physical challenges, including HD chorea, which are involuntary movements that often impact daily life.1,3 As Teva’s new Honestly HD ambassador, Will is sharing his own family’s story with HD to help connect people navigating the disease with educational resources and inspiration.

Will's introduction to the world of HD came through his wife, Olivia. They met when Olivia’s father, Dr. Douglas Modling Jr., was experiencing progression in his HD symptoms and about to enter an assisted living facility for additional care. Her brother, Douglas III (known as Doug), was diagnosed in 2022 and has found comfort in connecting with others living with HD. Inspired by their strength, Will began learning more about the disease, supporting his brother-in-law and joining Olivia’s family in advocating for the HD community.

“Seeing firsthand the challenges my brother-in-law faces, and his enduring hope despite it all, I'm incredibly inspired by the resilience of everyone I’ve met from the HD community. That’s why I’m sharing our story — to help raise awareness of this disease and let people know they are not alone, and that there are resources available to support them," said Will. "It's a hope I share with Teva — that we can empower people with stories like my family’s, or those beginning to experience symptoms like chorea, to connect with resources like Honestly HD and help preserve their independence for as long as possible."

HD is characterized by uncoordinated and uncontrollable movements, cognitive deterioration, and behavioral and/or psychological challenges.1 About 90% of people with HD will develop chorea, which manifests as involuntary body movements such as fidgeting, squirming or jerking that can affect the hands, face, limbs, torso, speech, and mobility.2 While it’s not the only symptom of HD, chorea can have a significant impact on daily activities and progressively limit peoples’ lives, which is why Teva is committed to supporting this community.

“We believe that progress starts with understanding, and that means listening to the real relationships and experiences that define the HD community every day,” said Heather DeMyers, Vice President, U.S. Innovative Medicines Marketing at Teva. “Will and Doug’s story captures the perseverance of so many families impacted by this disease. Their experience is one of inspiration, hope, and the importance of community — embodying the values of Teva’s work with Honestly HD as we strive to bring greater empathy and awareness to those navigating this disease.”

Visit HonestlyHD.com to learn more about HD and hear directly from Will and Doug about their HD story.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

About Chorea Associated with Huntington’s Disease (HD)

Huntington’s disease (HD) is a fatal neurodegenerative disease characterized by uncoordinated and uncontrollable movements, cognitive deterioration and behavioral and/or psychological problems. Chorea – involuntary, random and sudden, twisting and/or writhing movements – is one of the most striking physical manifestations of Huntington’s disease and occurs in approximately 90% of patients. Chorea can have a significant impact on daily activities and progressively limit peoples’ lives.1,2

Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize products for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

References:

1. Huntington’s Disease. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/huntingtons-disease#toc-what-is-huntington-s-disease-.
2. Thorley, E. M., Iyer, R. G., Wicks, P., Curran, C., Gandhi, S. K., Abler, V., Anderson, K. E., & Carlozzi, N. E. (2018). Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States. The patient, 11(5), 547–559. https://doi.org/10.1007/s40271-018-0312-x.
3. Huntington's Disease Society of America. “Overview of Huntington’s Disease.” Hdsa.org, Huntington’s Disease Society of America, 2019, www.hdsa.org/what-is-hd/overview-of-huntingtons-disease/.

Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
 
Teva Investor Relations Inquiries
TevaIR@Tevapharm.com